Bavarian CFO eyes a double jackpot
With just one approval of its small pox vaccine Imvamune in the US, Bavarian Nordic could create two new sources of revenue in the near future.
BY STEFAN SINGH KAILAY
Bavarian Nordic delivered slightly above expectations in 2016, with revenue of DKK 1,007 million (USD 144 million) and operating profit of DKK 33 million. And the biotech company can look forward to an even better 2017.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Bavarian shows encouraging data for RSV vaccine
For abonnenter
Bavarian Nordic begins combo trials with cancer vaccine
For abonnenter
